The Economic Value of MR-Imaging for Uveal Melanoma
Received 13 November 2019
Accepted for publication 3 March 2020
Published 28 April 2020 Volume 2020:14 Pages 1135—1143
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Lorna Grech Fonk,1,2 Teresa A Ferreira,2 Andrew G Webb,2,3 Gregorius PM Luyten,1 Jan-Willem M Beenakker1,2
1Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands; 2Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; 3C.J. Gorter Centre for High Field Magnetic Resonance Imaging, Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands
Correspondence: Lorna Grech Fonk
Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands
Objective: Uveal melanoma (UM) is the most common primary intra-ocular tumour. Treatment is determined by tumour size and location. Generally, smaller tumours are eligible for brachytherapy unless they are located close to posterior pole. Larger tumours are enucleated or undergo proton beam therapy (PBT), which is more expensive than brachytherapy and less available. Accuracy of tumour size determination is critical for accurate planning and delivery of treatment, particularly to ensure tumour coverage, critical structure sparing, and for the choice of treatment modality. This is particularly the case for tumour dimensions that are close to the cut-off point for a specific type of treatment: in the case of the brachytherapy protocol at our institution, 6– 8 mm. Ultrasound is conventionally used, but magnetic resonance imaging (MRI) has recently become an additional available tool. Although more expensive, it enables more accurate measurements and is particularly useful in combination with clinical fundus examination, fundus photography and ultrasound. Our aim in this paper was to determine the economic value of MRI for UM treatment.
Methods: We retrospectively analysed 60 patients’ MRI scans acquired as part of a study or for clinical care. For each patient, we assessed whether the extra cost of an MRI generated economic benefit or change in optimal treatment.
Results: MRI indicated a smaller tumour prominence than US in 10% of patients with intermediate tumour size, resulting in a change from PBT to brachytherapy. The costs of MRI, € 200–€ 1000, are significantly lower than the higher costs of PBT compared to brachytherapy, € 24,000 difference. In addition, the annual total economic burden of severe vision impairment associated with eye removal is € 10,000. Furthermore, for patients where ultrasound was impossible due to previous surgery, MRI enabled eye-preserving treatment.
Conclusion: An additional MRI for specific patients with UM improves economic value as it enables less expensive treatment in a sufficient percentage of patients to compensate for the MRI costs. Value is increased in terms of quality of care as it enables for some a treatment option which spares more vision.
Keywords: uveal melanoma, ocular tumour, MRI, radiotherapy, oncological imaging, ultrasound, eye diseases
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]